Condition: Lupus Nephritis · Systemic Lupus Erythematosus · Systemic Sclerosis (SSc) · Sponsor: Miltenyi Biomedicine GmbH
AID is a phase I multi-cohort study to assess the safety and tolerability of zamtocabtagene autoleucel (zamto-cel) in patients with refractory autoimmune diseases (SLE-Non renal, SLE-LN, SSc/dcSSc) after receiving standard therapy.
This description comes directly from the study's public registry record.
Sadie Swift · 617-218-0044 · clinicaltrials@miltenyi.com
Paris Jamiel · 617-218-0044 · clinicaltrials@miltenyi.com
Always discuss trial participation with your own doctor first.
| Froedtert Hospital and the Medical College of Wisconsin | Milwaukee, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06708845